Meeting News CoverageVideo

VIDEO: Plenary abstract ‘very impactful’ for patients with FLT3-mutated AML

ORLANDO, Fla. — Ruben A. Mesa, MD, offers his reaction to a plenary abstract from the ASH Annual Meeting and Exposition that showed the addition of midostaurin to standard induction chemotherapy prolonged survival in younger adults with FLT3-mutated acute myeloid leukemia.

ORLANDO, Fla. — Ruben A. Mesa, MD, offers his reaction to a plenary abstract from the ASH Annual Meeting and Exposition that showed the addition of midostaurin to standard induction chemotherapy prolonged survival in younger adults with FLT3-mutated acute myeloid leukemia.

    See more from ASH Annual Meeting and Exposition